MedTrace Logo

Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma

NCT05631613 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-12-29

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate properties of lipiodol-idarubicin emulsion mixed with the best regimen obtained in vitro study, including stability, viscosity，visibility under X-ray and deposition, in order to maximize the efficacy of idarubicin-cTACE for HCC.

Conditions

Interventions

PROCEDURE

cTACE(conventional transarterial chemoembolization)

transarterial chemoembolization with lipiodol-idarubicin emulsion

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Principal Investigators

  • Hai-Dong Zhu, MD · Zhongda hospital, Southeast university, Nanjing, China

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-28
Primary Completion
2023-03-31
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05631613 on ClinicalTrials.gov